Halozyme Therapeutics, Inc. (HALO)
$
57.63
+1.05 (1.82%)
Key metrics
Financial statements
Free cash flow per share
4.0235
Market cap
7.1 Billion
Price to sales ratio
6.5491
Debt to equity
3.1257
Current ratio
8.3923
Income quality
1.0381
Average inventory
153.4 Million
ROE
1.2224
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally, focusing on advancing drug delivery technologies. The company recorded an operating income of $551,475,000.00 reflecting its earnings from core operations, while incurring an interest expense of $18,095,000.00 indicative of its debt servicing obligations. The total costs and expenses for the company are $463,849,000.00 highlighting its overall spending. Additionally, the diluted EPS is $3.43 accounting for potential share dilution, and the company incurred an income tax expense of $113,041,000.00 indicating its tax obligations. Its flagship product, Hylenex recombinant, utilizes patented recombinant human hyaluronidase enzyme (rHuPH20) to facilitate subcutaneous fluid administration, enhancing the dispersion and absorption of other injected drugs. The company develops several important therapeutics including Perjeta, RITUXAN HYCELA, and MabThera SC for non-Hodgkin lymphoma, as well as HYQVIA for immunodeficiency disorders. Furthermore, collaborations with several renowned organizations support its innovative efforts in treating various conditions. The stock is affordable at $57.63 suitable for budget-conscious investors, which, combined with a high average trading volume of 2,644,956.00 indicates strong liquidity. With a mid-range market capitalization of $7,101,226,230.00 the company is a steady performer in the competitive landscape of the Biotechnology industry. As a key player in this sector, it significantly contributes to the overall market landscape, driving innovation and growth. In addition to its successful products, the company is actively developing treatments such as Tecentriq for non-small cell lung cancer and OCREVUS for multiple sclerosis, alongside other promising therapies aimed at a variety of serious health conditions. Halozyme's extensive collaborations with top pharmaceutical companies also underscore its commitment to addressing unmet medical needs and advancing healthcare outcomes globally.
Is Halozyme Therapeutics, Inc. (HALO) a good investment?
Investing in Halozyme Therapeutics, Inc. (HALO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Halozyme Therapeutics, Inc. (HALO)'s stock forecast?
Analysts predict Halozyme Therapeutics, Inc. stock to fluctuate between $42.01 (low) and $70.51 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Halozyme Therapeutics, Inc.'s market capitalization?
As of 2025-07-10, Halozyme Therapeutics, Inc.'s market cap is $7,101,226,230, based on 123,221,000 outstanding shares.
How does Halozyme Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Halozyme Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Halozyme Therapeutics, Inc. (HALO) stock?
To buy Halozyme Therapeutics, Inc. (HALO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for HALO. Place an order (Market, Limit, etc.).
What is the best time to invest in Halozyme Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Halozyme Therapeutics, Inc. perform in the last earnings report?
Revenue: $1,015,324,000 | EPS: $3.50 | Growth: 64.32%.
Where can I find Halozyme Therapeutics, Inc.'s investor relations reports?
Visit https://www.halozyme.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Halozyme Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Halozyme Therapeutics, Inc. stock?
All-time high: $70.51 (2025-05-07) | All-time low: $29.85 (2023-05-09).
What are the key trends affecting Halozyme Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
prnewswire.com
SAN DIEGO , June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market close on June 27 th, as part of the 2025 FTSE Russell indexes annual reconstitution. The Russell 1000® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by investors as a benchmark for the performance of large-cap stocks.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
prnewswire.com
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO , June 20, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than 30 years.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
zacks.com
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
prnewswire.com
Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union SAN DIEGO , May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received European Commission (EC) approval of a new Opdivo® (nivolumab) subcutaneous formulation developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for use across multiple adult solid tumors as monotherapy, monotherapy maintenance following completion of intravenous nivolumab plus Yervoy® (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. "The European approval of Opdivo SC represents an advancement for certain cancer patients, who now have the option to receive their Opdivo as a 3-to-5-minute SC injection," said Dr. Helen Torley, president and chief executive officer of Halozyme.
See all news
